Brief: Nymox reports additional positive data from fexapotide BPH phase 3 trial
29/11/2016 14:45
Nov 29 (Reuters) - Nymox Pharmaceutical Corp NYMX.O :
* Nymox reports additional positive results from completed
fexapotide BPH phase 3 studies showing significant early
response and first-line efficacy
* New phase 3 results indicate that fexapotide in trials was
highly efficacious for first-line treatment of BPH
Source text for Eikon: ID:nGNXNNGSDa
Further company coverage: NYMX.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Nymox Pharmaceutical
See all newsBrief: Nymox Says Required To Resubmit Application To DKMA
Brief: Nymox Pharmaceutical Corp Says Terminated Employment Of Christopher R Riley As CFO (June 27)
Brief: Nymox Announces Appointment Of Christopher R. Riley As Chief Financial Officer
Brief: Nymox Appeals Deficiency Letter
U.S. STOCKS ON THE MOVE-Pot stocks, Nymox, Zynerba